Rheumatology International

Papers
(The H4-Index of Rheumatology International is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review292
Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management212
SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis114
Willingness to get the COVID-19 vaccine among patients with rheumatic diseases, healthcare workers and general population in Turkey: a web-based survey91
ANCA-associated vasculitis after COVID-1985
Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment84
High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study77
Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic77
Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes75
Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly71
Postdischarge rheumatic and musculoskeletal symptoms following hospitalization for COVID-19: prospective follow-up by phone interviews69
YouTube as a source of information on gout: a quality analysis68
COVID-19 vaccine hesitancy in patients with systemic autoimmune rheumatic disease: an interview-based survey67
Kawasaki-like disease in children with COVID-1963
The psychological state and changes in the routine of the patients with rheumatic diseases during the coronavirus disease (COVID-19) outbreak in Turkey: a web-based cross-sectional survey62
Can the SARS-CoV-2 infection trigger systemic lupus erythematosus? A case-based review61
The Beighton Score as a measure of generalised joint hypermobility61
Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease—a randomised controlled trial60
Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey58
Comorbidities in psoriatic arthritis: a systematic review and meta-analysis56
Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic53
Telemedicine for patients with rheumatic and musculoskeletal diseases during the COVID-19 pandemic; a positive experience in the Netherlands53
Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis52
Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry50
Multiple system inflammatory syndrome associated with SARS-CoV-2 infection in an adult and an adolescent47
COVID-19 pandemic in Japan46
Reactive arthritis after COVID-19: a case-based review45
ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: case-based review43
Management of childhood-onset autoinflammatory diseases during the COVID-19 pandemic41
Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis40
Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study37
The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk37
COVID-19 vaccination in autoimmune disease (COVAD) survey protocol36
Impact of COVID-19 pandemic on rheumatoid arthritis from a Multi-Centre patient-reported questionnaire survey: influence of gender, rural–urban gap and north–south gradient35
Teleconsultation experience with the idiopathic inflammatory myopathies: a prospective observational cohort study during the COVID-19 pandemic34
0.081885814666748